- Climb Bio's newest candidate, **Climb 116**, a next-generation anti-APRIL sweeper antibody for IgA nephropathy, is expected to enter the clinic in **Q4 this year**.  **[1768446_2160733_1]** **[1768446_2160733_2]**  Preclinical data indicates a **two to three times longer half-life** and **deeper, more durable IgA reductions** (over 70% reduction) compared to first-generation anti-APRIL agents.  **[1768446_2160733_2]** **[1768446_2160733_10]** **[1768446_2160733_12]** 
- Initial data from the Phase 1 trial for Climb 116 is anticipated **mid-year 2026**.  **[1768446_2160733_2]** **[1768446_2160733_14]** 
- The company's lead asset, **BDO PROTEG**, a B-cell-depleting DD19 monoclonal antibody, has four trials actively enrolling for systemic lupus erythematosus, immune thrombocytopenia, primary membranous nephropathy, and subcutaneous formulations.  **[1768446_2160733_1]**

Climb Bio Provides Preclinical Data and Clinical Development Update for Climb 116

- Climb Bio expects to **initiate Phase 1 for CLYM116 in IgA Nephropathy in Q4 2025** and anticipates **initial Phase 1 data in mid-2026**.  **[1768446_2160666:5]** 
- The company also projects **initial data for Budoprutug SC anti-CD19 in autoimmune disease in H1 2026**.  **[1768446_2160666:5]** 
- The target market for CLYM116, IgA Nephropathy, represents an **estimated $10-20 billion opportunity** in the US.  **[1768446_2160666:7]**

Climb Bio (CLYM)